Experimental Weekly Drug Shows Promise for Weight Loss and Blood Sugar Control

People who live with both obesity and type 2 diabetes often get caught in a frustrating cycle.

Carrying extra weight can make blood sugar harder to manage, while diabetes can also make significant weight loss more difficult.

New late-stage trial results indicate that retatrutide, an experimental medicine taken once a week, may address both problems at once. The drug targets three hormone pathways involved in appetite, glucose control, and energy expenditure.

In the study, researchers enrolled 1,152 adults with type 2 diabetes and a body mass index of at least 27. Participants were randomly assigned to receive 4 mg, 9 mg, or 12 mg of retatrutide, or a placebo, over 80 weeks.

The weight-loss results were striking. In the main analysis, people taking retatrutide lost an average of 11.9% to 18.8% of their starting weight, depending on dose, compared with 5.1% in the placebo group.

The 12 mg dose produced the strongest effect. Nearly half of those participants lost at least 20% of their body weight, and almost one-third shed 25% or more.

The treatment also improved diabetes control. Average HbA1c, which reflects blood sugar levels over several months, dropped by about 1.4 to 1.5 percentage points in the retatrutide groups, versus 0.45 points with placebo.

That matters because type 2 diabetes can slowly damage blood vessels and organs over time. The trial also showed improvements in several markers linked to heart and metabolic health, including blood pressure and blood fats related to cholesterol.

There were downsides, though. Diarrhea affected about 27% to 34% of people taking retatrutide, while nausea affected about 14% to 28%; both side effects were less common in the placebo group.

Higher doses were also associated with more low blood pressure and unusual skin sensations. Some participants discontinued treatment because of side effects, underscoring that a drug can be highly effective while still being hard for some patients to tolerate.

The TRIUMPH-2 study was published in The Lancet and presented at the European Association for the Study of Diabetes meeting in Milan. Eli Lilly, the company developing retatrutide, funded the trial.

The results stand out because the research was a large phase 3 randomized trial and most participants completed it. The scale of the changes in weight and blood sugar suggests the medicine could become an important option if regulators conclude that its benefits outweigh its risks.

Still, the trial followed participants for about a year and a half, which is not long enough to answer every safety question over many years. It also does not show whether the improvements in weight, blood sugar, blood pressure, and blood fats will translate into fewer heart attacks or other major complications.

Retatrutide therefore appears promising, but the picture is not complete. More studies are needed to confirm long-term safety, determine whether the benefits last, and compare it directly with other strong obesity and diabetes treatments.

If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight.

For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.

Source: Los Angeles Institute for Metabolic Research.